ReviewClinical and molecular allergy : CMA2016
Burden of allergic respiratory disease: a systematic review.
Review in Clinical and molecular allergy : CMA, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 1 synthesis or guideline pooled it, 148 citations in OpenAlex.
- Clinical Practice Guideline: Immunotherapy for Inhalant Allergy.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2024Guideline
- Efficacy and Safety of a Drug-Free, Barrier-Forming Nasal Spray for Allergic Rhinitis: Randomized, Open-Label, Crossover Noninferiority Trial.International archives of allergy and immunology · 2023Trial
- Nasal administration of a probiotic assemblage in allergic rhinitis: A randomised placebo-controlled crossover trial.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2022Trial
- [The comparison of step-down pharmacotherapy and maintaining dose therapy for seasonal allergic rhinitis].Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery · 2020Trial
- Sublingual house dust mite immunotherapy has no impact on decrease of circulating erythrocytes upon airway allergen challenge in allergic rhinitis.Scientific reports · 2017Trial
- Safety and Effectiveness of Subcutaneous Immunotherapy with an Undiluted Glutaraldehyde-Polymerized Pollen Extract Mixture in Adults and Children with Allergic Rhinitis with or Without Asthma Due to Olive and Grass Pollen.Diseases (Basel, Switzerland) · 2026Article
- Steroid Sparing Effect of 300IR House Dust Mite Sublingual Immunotherapy Tablet in Mite Allergic Rhinitis.Clinical and translational allergy · 2026Article
- Article
- The Bioactivity ofCurrent issues in molecular biology · 2026Article
- Early-Life Ozone Exposure and Childhood Allergic Rhinitis: Critical Exposure Windows, Exposure-Response Relationships, and Protective Modifiers.Environment & health (Washington, D.C.) · 2026Article
- Molecular profiling of IgE sensitization to dermatophagoides allergen components: clinical correlates in a high-exposure region.Frontiers in allergy · 2026Article
- Real-Life Assessment of Multi-Pollutant Exposure and Its Impact on the Ocular Surface: The Bike-Eye Pilot Study on Urban Cyclists in Bologna.International journal of environmental research and public health · 2025Article
- Investigating allergic rhinitis effects on laryngopharyngeal reflux in Sudanese people during the Sudanese armed conflict.Scientific reports · 2025Article
- Potential use of plant secondary metabolites in the treatment of allergic respiratory diseases (ARDs).Molecular biology reports · 2025Review
- Sensitization to inhaled and food allergen sources in patients with allergic diseases in Eastern China.Frontiers in allergy · 2025Article
- Association of pyrethroids exposure with asthma in US children and adolescents: a nationally representative cross-sectional study.European journal of pediatrics · 2024Article
- Safety of 300IR house dust mite sublingual tablet from pooled clinical trial and post-marketing data.The World Allergy Organization journal · 2024Article
- Executive Summary of Clinical Practice Guideline on Immunotherapy for Inhalant Allergy.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2024Article
- Barrier-forming, drug-free nasal spray reduces allergic symptoms induced by house dust mite allergen.Clinical and translational allergy · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This meta-analysis compared the health-related quality of life (HRQL) of patients with allergic rhinitis (AR) and/or allergic asthma (AA) caused by perennial house dust mite (HDM) versus AR and/or AA caused by seasonal pollen allergy. Following a systematic search, the identified studies used the disease-specific rhinitis quality of life questionnaire or generic instruments (SF-36 and SF-12). Summary estimates obtained by meta-analysis showed that HRQL in patients with perennial HDM allergy was significantly worse than that of patients with seasonal pollen allergy, when measured by both disease-specific and generic HRQL instruments, and was reflected by an impact on both physical and mental health. A systematic review of cost data on AR and AA in selected European countries demonstrated that the majority of the economic burden was indirectly caused by high levels of absenteeism and presenteeism; there was little or no evidence of increasing or decreasing cost trends. Increased awareness of the detrimental effects of AR and/or AA on patients' HRQL and its considerable cost burden might encourage early diagnosis and treatment, in order to minimize the disease burden and ensure beneficial and cost-effective outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.